146 related articles for article (PubMed ID: 38054392)
1. Sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists treatment: variable observations of sequelae on diabetic retinopathy.
Varughese GI; Jacob S
J R Soc Med; 2023 Dec; 116(12):408. PubMed ID: 38054392
[No Abstract] [Full Text] [Related]
2. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).
Lin TY; Kang EY; Shao SC; Lai EC; Hwang YS
Diabetes Metab J; 2023 Jul; 47(4):573-574. PubMed ID: 37533200
[No Abstract] [Full Text] [Related]
3. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).
Ko J; Moon SJ
Diabetes Metab J; 2023 Jul; 47(4):571-572. PubMed ID: 37533199
[No Abstract] [Full Text] [Related]
4. Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.
Kalra S; Bhattacharya S; Kapoor N
J Pak Med Assoc; 2022 May; 72(5):989-990. PubMed ID: 35713074
[TBL] [Abstract][Full Text] [Related]
5. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
[TBL] [Abstract][Full Text] [Related]
6. In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA
Tanner M
Ann Intern Med; 2020 Nov; 173(10):JC52. PubMed ID: 33197349
[TBL] [Abstract][Full Text] [Related]
7. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
[TBL] [Abstract][Full Text] [Related]
8. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
[TBL] [Abstract][Full Text] [Related]
9. The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.
Liu M; Hao G
Eur J Prev Cardiol; 2023 Jun; 30(8):656-657. PubMed ID: 36740456
[No Abstract] [Full Text] [Related]
10. Sodium-glucose co-transporter 2 inhibitors & glucagon-like peptide-1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients.
Mahmoud T; Yagan J; Hasan A; Gheith OA; Mostafa M; Rida S; El-Serwi N; Shaker M; Khalid M
Clin Transplant; 2023 Dec; 37(12):e15144. PubMed ID: 37755118
[TBL] [Abstract][Full Text] [Related]
11. Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.
Zaccardi F; Kloecker DE; Khunti K; Davies MJ
Diabetes Obes Metab; 2022 Aug; 24(8):1598-1606. PubMed ID: 35491523
[TBL] [Abstract][Full Text] [Related]
12. Optimising renal risk parameters in type 2 diabetes mellitus: Perspectives from a retinal viewpoint.
Jacob S; Varughese GI
Clin Med (Lond); 2024 Mar; 24(2):100031. PubMed ID: 38369127
[TBL] [Abstract][Full Text] [Related]
13. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?
Vincent RK; Williams DM; Evans M
Diabetes Obes Metab; 2020 Dec; 22(12):2227-2240. PubMed ID: 32945071
[TBL] [Abstract][Full Text] [Related]
14. Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes.
Alduraibi RK; Alrebdi YM; Altowayan YF
Medicine (Baltimore); 2023 Jun; 102(23):e34027. PubMed ID: 37335652
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
[TBL] [Abstract][Full Text] [Related]
16. Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Kobayashi K; Toyoda M; Hatori N; Sakai H; Furuki T; Chin K; Kimura M; Saito N; Kanaoka T; Aoyama T; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Machimura H; Hishiki T; Umezawa S; Shimura H; Nakajima S; Yamamoto H; Sato K; Miyakawa M; Terauchi Y; Tamura K; Kanamori A
Diabetes Res Clin Pract; 2022 Mar; 185():109231. PubMed ID: 35131376
[TBL] [Abstract][Full Text] [Related]
17. Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome.
Premji R; Nylen ES; Naser N; Gandhi S; Burman KD; Sen S
Metab Syndr Relat Disord; 2022 Aug; 20(6):321-328. PubMed ID: 35452324
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?
Patoulias D; Papadopoulos C; Doumas M
Int J Cardiol; 2021 Jan; 323():259. PubMed ID: 32810546
[No Abstract] [Full Text] [Related]
19. Cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The P value and beyond.
Kloecker DE; Davies MJ; Khunti K; Zaccardi F
Diabetes Obes Metab; 2021 Jul; 23(7):1685-1691. PubMed ID: 33764645
[TBL] [Abstract][Full Text] [Related]
20. Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis.
Tan L; Wang Z; Okoth K; Toulis KA; Denniston AK; Singh BM; Crowe FL; Sainsbury C; Wang J; Nirantharakumar K
Front Endocrinol (Lausanne); 2023; 14():1303238. PubMed ID: 38239984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
